With a Phase III program to fund for its promising anti-inflammatory drug obefazimod in ulcerative colitis (UC), Abivax SA has raised €49.2m to extend its cash runway to the end of the first quarter of 2023.
The French firm said that the oversubscribed financing involved "high-quality US and European biotech specialist investors" led by TCGX, with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?